<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: CD33 is a cell surface antigen for committed myelomonocytic lineage </plain></SENT>
<SENT sid="1" pm="."><plain>We explored the potential of detecting CD33 as cell-free circulating protein in patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: We developed a quantitative bead-based immunoflow cytometry assay to measure cell-free circulating CD33 (cCD33) levels in the plasma of patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, and correlated these results with corresponding clinical behavior </plain></SENT>
<SENT sid="3" pm="."><plain>We measured cCD33 levels in the plasma of 48 healthy subjects and in patients with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (n = 98), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (n = 46), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (n = 50), and <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> (n = 49) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> and <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> had significantly higher concentrations of cCD33 than the other patient groups and <z:mpath ids='MPATH_458'>normal</z:mpath> individuals (p = 0.0001), and among these groups, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients displayed the lowest cCD33 levels (p = 0.02) </plain></SENT>
<SENT sid="5" pm="."><plain>Circulating CD33 values correlated positively with the CD33(+) blast cell counts in these patients </plain></SENT>
<SENT sid="6" pm="."><plain>While there was no correlation between cCD33 levels and survival in <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, higher cCD33 plasma concentrations did correlate with shorter survival in <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (p = 0.03), and with shorter complete remission duration in <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (p = 0.04) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (p = 0.03) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Circulating CD33 can be detected in the plasma from patients with <z:hpo ids='HP_0001909'>leukemias</z:hpo>, and cCD33 levels may have clinical implication, e.g., predictive and prognostic value, in these patients </plain></SENT>
</text></document>